SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as community members discuss its upcoming presentation with NVIDIA and potential catalysts, including One Amazon. The discussion includes opinions on contracts and the company's overall direction. Some are focused on potential short squeezes.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla's stock is trending upwards, fueled by optimism around potential Federal Reserve rate cuts and excitement surrounding the company's energy storage business, including the Megapack 3 and Megablock systems. The community is also discussing the ambitious performance-based compensation package for Elon Musk, tying his compensation to aggressive milestones in robotics and AI, while some express concern over Elon Musk's renewed engagement in political matters and its potential impact on the brand.

Biggie is a popular Pitbull across several social media platforms, such as Tiktok, Youtube and Instagram. With a blend of creativity and comedic gestures, Biggie brings animal loving entertainment to millions of viewers through images, videos and reels. With Biggie the Pitbull's growing popularity, the meme coin $BIGGIE was inspired and launched on the ethereum network, leveraging Biggies unique sense of humor and style.

Biggie

Biggie crypto is trending, with community members discussing where to purchase it and its potential. Some users suggest the increase in attention could lead to further movement, while others believe there may be bot activity.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders debate whether natural gas can sustain its recent gains amid mixed signals, including high storage levels and fluctuating weather forecasts. Community members are closely watching technical indicators and storage reports, with some expressing skepticism about the rally's longevity while others anticipate a winter squeeze. Discussions also involve the impact of LNG exports and potential production changes on the overall supply picture.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around this Solana-based meme coin, which is built on a joke. The project is focused on charitable donations, particularly to animal shelters, and boasts a strong, active community. Talk centers around its potential for growth within the dog-themed crypto space and recent listing on Jupiter Exchange.

Pump.fun

$PUMP.X is trending as traders discuss its potential as a leading platform in the memecoin space, with some drawing comparisons to the early days of Dogecoin. Community members are actively speculating on potential price targets and future exchange listings, while also debating the merits of its underlying platform.

PolySwarm

PolySwarm is gaining attention as traders speculate on a potential breakout, fueled by rising volume and discussions around cybersecurity's growing importance. Community members are closely watching for a catalyst that could trigger a significant price movement, with some pointing to the upcoming week as a potentially volatile period for altcoins. Bullish sentiment is building, centered around the token's utility and the anticipation of a substantial pump.

What is the project about? The Helium Network is a decentralized, blockchain-based wireless infrastructure project that allows individuals and organizations to deploy and operate wireless networks through token incentivization. It leverages the Solana Blockchain for its foundation. The primary token powering the network is HNT, while IOT and MOBILE tokens are used to facilitate the LoRaWAN and 5G networks, respectively.  What makes your project unique? Decentralized Infrastructure: The Helium Network allows for the creation and maintenance of a distributed wireless network by incentivizing participants to contribute resources and share the benefits. Scalable and Secure: The network leverages the Solana Blockchain, which is known for its high scalability, low latency, and robust security. Multi-Use Case Support: The Helium Network supports various use cases, including IoT devices through the LoRaWAN network and high-speed mobile connectivity via the 5G network. Incentivized Participation: The Helium Network employs a token-based system to reward participants and encourage network growth. Proof-of-Coverage (PoC): A unique consensus algorithm employed by the LoRaWAN and 5G subnetworks, which rewards participants for verifying wireless network coverage.  What’s next for your project? Today, the Helium Network is a rapidly growing decentralized wireless infrastructure with a global footprint. It continues to attract new users, developers, and organizations, paving the way for innovative applications and services. As the network expands, it aims to revolutionize the wireless communication landscape and further democratize access to connectivity  What can your token be used for? The MOBILE token is the Governance token of the 5G Subnetworks, mined by 5G Hotspots through both data transfer proceeds as well as Proof of Coverage.

Helium Mobile

Helium Mobile ($MOBILE.X) is trending amid discussions about its future utility and potential for price movement, with some traders hoping for a pump. The community is actively debating the impact of past events such as Coinbase delisting, and whether MOBILE will follow Helium ($HNT.X) in a potential rally. Some users highlight ongoing partnerships, while others express concerns about its long-term value.

Oscar is a famous meme featuring a Shiba on a trampoline that went viral on the internet. It was also the first meme Ryoshi used when he introduced the Shiba Inu token to the world in the well-known Medium article titled All Hail The Shiba! (August 2, 2020).  Oscar appears in this article, with Ryoshi himself commenting, “Next we tell some more frens and WOW MOON LAMBO PUMPPPPPPY." Many might say this was Ryoshi’s own prophecy, predicting that Oscar would one day come into existence.  Now, Oscar is a CTO token embraced and guided by the Shiba community, and it also enjoys the support of Paradox Designer. Paradox was alongside Ryoshi from day one of the Shiba Inu token's creation, playing a crucial role in its success as the first member in Ryoshi’s Telegram group and also on Discord. Moreover, Paradox Designer is the artist behind the iconic Shiba Inu token logo, which is now recognized and famous worldwide.

OSCAR

$OSCAR.X is trending as the community focuses on its mission to feed stray dogs and build a 'crypto for good' ecosystem on the Ethereum and Shibarium blockchains. Community members highlight the project's roots as the original Shiba Inu meme and its ongoing development of DeFi utilities like staking for $COLLAR. The recent buzz is around its charity initiatives and the ability to make a tangible impact with micro-donations.

Airship AI Holdings, Inc. engages in a video, sensor, and data management surveillance platform which focuses on the provision of software services. Its products include Airship Acropolis OS, Airship Command, and Airship Outpost. The company was founded by Derek Xu on June 30, 2003 and is headquartered in Redmond, WA.

Airship AI Holdings Inc - Ordinary Shares - Class A

AISP is trending amid discussions of government contracts and potential benefits from the "Big Beautiful Bill," particularly regarding border security and AI initiatives. The community is actively debating the stock's valuation, potential for a short squeeze, and the significance of insider buying, while awaiting news of contract awards. Some investors are speculating on a potential acquisition, and the warrants are seen as undervalued.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IOVA Stock Drops 6% on $350M Common Stock Offering

Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline. 

Shares of Iovance Biotherapeutics Inc. (IOVA) traded 4% higher on Tuesday morning after Health Canada approved the company’s immunotherapy for the treatment of advanced melanoma.On Stocktwits, retail sentiment around IOVA rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter around <a href="https://stocktwits.com/symbol/IOVA">IOVA</a> jumped 782% over the past 24 hours as of Tuesday's early hours and by 87% over the past seven days.<figure class="image"><img style="aspect-ratio:626/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_11_53_05_AM_png_6c5efda32c.webp" alt="IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="61"><figcaption>IOVA's Sentiment Meter and Message Volume as of 11:50 a.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock would have risen further had it not been for an overall market downturn and said that ‘patience will pay off.’<stembedurl>https://stocktwits.com/katanare/message/625784957</stembedurl>Iovance’s Amtagvi is a T-cell immunotherapy for the treatment of adult patients with unresectable or metastatic melanoma that has progressed on or after at least one prior systemic therapy and who have no satisfactory alternative treatment options. Advanced melanoma, also known as metastatic melanoma, refers to melanoma that has spread from the original site to other parts of the body.The marketing authorization in Canada was <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvir-lifileucel-receives-health-canada-approval">granted</a> based on the safety and efficacy results from a mid-stage trial. The approval is conditional, pending results of trials to confirm its clinical benefit. However, for Iovance, the approval marks its first outside the U.S. “We expect to authorize our first Canadian treatment center within the next few months, and we continue to advance our ex-U.S. strategy for Amtagvi in additional markets,” said CEO Frederick Vogt.Iovance is also investigating Amtagvi in frontline advanced melanoma in a late-stage trial, as well as in additional solid tumor types. IOVA stock is down by 65% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/william-blair-highlights-tesla-robotaxi-upsides-versus-uber-waymo/chsgZU4RdgC">William Blair Highlights Tesla Robotaxi’s Upsides Versus Uber, Waymo: Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Iovance Biotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’

The approval from Health Canada is conditional, pending results of trials to confirm the immunotherapy’s clinical benefit.

Equity

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Iovance Biotherapeutics have dropped over 17% so far this week, on course to mark their worst weekly decline since mid-November 2024.&nbsp;The selloff aligns with broader pressure on small-cap stocks within the Russell 2000 index, which is sliding into correction territory as fears over prolonged higher interest rates grip the market.Macroeconomic concerns have intensified following robust U.S. jobs data, showing accelerating job growth and a lower unemployment rate of 4.1% in December.&nbsp;Small and mid-cap companies, like Iovance, are particularly sensitive to rate dynamics due to their reliance on borrowing compared to larger companies.<figure class="image"><img style="aspect-ratio:1314/1036;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/IOVA_poll_sentiment_and_message_volume_Jan_10_95fa61f76a.png" alt="IOVA poll sentiment and message volume Jan 10.png" width="1314" height="1036"><figcaption>IOVA poll sentiment and message volume Jan 10 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the macro-driven plunge, sentiment for Iovance has turned ‘extremely bullish’ on Stocktwits, with the stock becoming one of the platform’s top three trending tickers on Friday afternoon.&nbsp;Many retail investors see the selloff as overdone, drawing attention to the company’s promising medical pipeline and proprietary technology.<stembedurl>https://stocktwits.com/thebullofwallst/message/599572619</stembedurl><stembedurl>https://stocktwits.com/parsnips/message/599576937</stembedurl>Some also speculated on the possibility of acquisition interest, citing Vertex Pharmaceuticals’ $4.9 billion premium buyout of Alpine Immune Sciences in 2024 as a precedent.&nbsp;<stembedurl>https://stocktwits.com/AngusMacbeth/message/599584221</stembedurl>In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers. "As a fully integrated company, Iovance is well positioned to remain the global leader in innovating, developing, and delivering current and future generations of TIL cell therapy for patients with cancer," he added.Tumor-infiltrating lymphocyte (TIL) therapy is an innovative, patient-specific approach that uses T-lymphocytes derived from a patient’s tumor to combat cancer cells.Retail optimism about TIL therapy remains high, with 67% of respondents in a Stocktwits poll calling it a “game-changer” in cancer treatment.&nbsp;The therapy this week gained visibility as MedStar Georgetown University Hospital became the first in the Washington, D.C., area to offer it for metastatic melanoma.Iovance’s retail following has grown by 65% over the past year, even as the stock has shed more than 30% during the same period.The company’s stock remains a battleground for investors, with short interest hovering at 19.5%.&nbsp;While macroeconomic challenges weigh on small caps, retail investors remain steadfast in their optimism, betting on TIL therapy’s transformative potential to reshape cancer treatment.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown

In November, Iovance CEO Frederick Vogt highlighted the strong U.S. launch of Amtagvi for advanced melanoma and its growing demand through an expanding network of authorized treatment centers.

Iovance Stock Tumbles On Macro Concerns, But Retail Stays Bullish On TIL Cancer Therapy Potential

This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?

Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon PR Newswire VANCOUVER, BC, Nov. 14, 2024 USA News...

A Peek at Iovance Biotherapeutics's Future Earnings

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.25	--	--	N/A
Q2 '25	-$0.28	-$0.33	-16.70%	MISSED
Q1 '25	-$0.24	-$0.36	-48.93%	MISSED
Q4 '24	-$0.27	-$0.26	2.88%	BEAT
Q3 '24	-$0.30	-$0.28	6.31%	BEAT

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest IOVA News

IOVA Iovance Biotherapeutics Inc